Docstoc

Siegel

Document Sample
Siegel Powered By Docstoc
					The National Oncologic PET Registry:
 Background and Operational Overview

            Barry A. Siegel, M.D.
     Mallinckrodt Institute of Radiology
               St. Louis, MO
Medicare Coverage for Oncologic PET
  • CMS coverage decisions from 1998 to 2004 were cancer-
    and indication-specific (unwieldy approach)
  • Diagnosis, staging, and restaging of:
       Non-small cell lung cancer Lymphoma
       Esophageal cancer          Malignant melanoma
       Colorectal cancer                Head and neck cancer
  •   Staging, restaging, and Rx monitoring of breast cancer
  •   Detection of thyroid cancer
  •   Staging of cervical cancer
  •   Mechanism announced in November 2004 to cover all
      other cancers and indications–National Registry
                         NOPR:
           A Nationwide Collaborative Program
                                               Advisor
Sponsored by

Managed by

Endorsed by
   • Chair, Bruce Hillner, MD, Virginia Commonwealth University
   • Co-chair, Barry A. Siegel, MD, Washington University
   • R. Edward Coleman, MD, Duke University
   • Anthony Shields, MD, PhD Wayne State University
   • Statistician: Dawei Liu, PhD, Fenghai Duan, PhD, Brown
     University
   • Epidemiologist: Ilana Gareen, PhD, Brown University
The National Oncologic PET Registry (NOPR)

• Is a CMS-approved
   – “Coverage with Evidence Development” Program
• Developed for the November 2004 expansion by CMS
   – All other cancers and indications except:
       • Breast cancer diagnosis and axillary staging
       • Melanoma regional nodal staging
Objectives
• Assess the effect of PET on referring physicians’ plans
  of intended patient management
   – across a wide spectrum of cancer indications for
     PET not currently covered by the Medicare
     program, and
   – in relation to cancer-type, indication, performance
     status, physician’s role in management, and type of
     PET.
Goal
•   Provide access to the service (PET)

•   Minimize the burden to patients, PET facilities, and referring physicians

•   Generate evidence of reasonable quality to assist CMS in deciding
    whether to expand coverage of PET

•   Registry to be financially self-supporting

•   How is the NOPR funded?
     – Start-up funding provided by AMI
     – NOPR is expected to be self-sufficient by collection of registration
       fees from participating PET facilities
         • $50 per facility
         • $50 per patient
    Who owns the NOPR data?
    • The Academy of Molecular Imaging, as an agent of CMS,
      will maintain ownership of the data collected by American
      College of Radiology (ACR) for the NOPR. The data
      reside in an electronic database at ACR.


    Who has access to NOPR data?
    • The members of the NOPR Working Group, NOPR project
      staff at ACR and the Center for Statistical Sciences at
      Brown University, and staff of CMS.




7
Participation Requirements/Responsibilities - PET
Facilities
• Any PET facility approved to bill CMS for either technical or
  global charges can participate in the NOPR.
• Willingness to take on the burden and additional cost of
  collecting data and sending to NOPR (including NOPR fees)

Participation Requirements – Patients
• Medicare beneficiaries, including those with Medicare HMO
  coverage, who are referred for FDG-PET for essentially all
  oncologic indications not currently reimbursable under Medicare.
• Oral consent is necessary for inclusion in the NOPR research
  dataset; however, no consent is necessary to submit data to
  NOPR that must be sent to CMS.
Referring Physician Responsibilities

• Complete Pre-PET Form (5 questions) and return it to PET
  Facility prior to PET scan.
• Complete Post-PET Form (4 -7 questions) and return it to PET
  Facility within 30 days of PET scan.
• No Medicare payment to referring physicians for completing the
  Pre- and Post-PET Forms.
• Referring MD cooperation essential to the success of this
  CED program
   NOPR Workflow

                                          PET                                 Ongoing
Referring MD      Ask patient
                                PET    interpreted                             patient
requests PET      for consent   done   & reported                            management




        Pre-PET                             Post-PET                      Post-PET Form
          Form                              Form sent,                      completed.
                                       including question for referring
                                                MD consent                Claim submitted
Pre-PET Form – 5 Questions
• Reason for the PET Scan
• Cancer Site/Type
• Summary of Disease Stage
   – NED, Localized, Regional, Metastatic, Unknown
• Performance Status
   – Asymptomatic, Symptomatic, Bedridden
• Intended Patient Management Plan
Pre-PET Form: Intended Patient Management

If PET were not available, your current management strategy
would be (select one)?
Pre-PET Form: Specific Reason For PET
Check the single best match for the reason for the PET scan.
   Diagnosis
      To determine if a suspicious lesion is cancer
      Unknown primary tumor: To detect primary tumor site in patient with confirmed /strongly suspected
         metastatic disease
      To detect primary site in patient with presumed paraneoplastic syndrome
   Known Cancer
      Initial staging of histologically confirmed, newly diagnosed cancer
      Restaging after completion of therapy
      Suspected recurrence of a previously treated cancer
   Monitoring treatment response during chemotherapy, radiotherapy, or combined modality therapy
   Observation (with close follow-up)
   Additional imaging (CT, MRI) or other non-invasive diagnostic tests
   Tissue biopsy (surgical, percutaneous, or endoscopic).
   Treatment (if treatment is selected, then also complete the following)
       Treatment Goal: (check one)  Curative  Palliative
       Type(s): (check all that apply)
      –      Surgical  Chemotherapy (including biologic modifiers)
      –      Radiation  Other  Supportive care
Post-PET Form – 4 to 7 Questions
• Questions customized by specific indication for PET
• Yes or no answer for majority
• Two questions repeated from the Pre-PET Form
   – Intended Patient Management Plan

   – Planned Cancer Care Provider

• Referring physician consent
NOPR Web Site
•   Information for
     – PET Facilities
     – Referring Physicians
     – Patients
•   Blank Forms
•   Register PET Facilities
•   Register Patients
•   Data Entry
•   PET Facility Tools
     – Case Status Reports
     – Account Balance
     – Fund Account by Credit Card
                                     March 2006
Pre-PET
Web Form




           2.




                42 Primary and Metastatic Sites Listed
Pre-PET
Web Form
continued
Issues Prior to Launch
• Determination made that NOPR data collection was exempt from
  “Common Rule” requirements for research.
• HIPAA requirements met through execution of a Business
  Associates Agreement with the American College of Radiology
  as an agent for the Academy of Molecular Imaging and CMS.
• Paperwork Reduction Act requirements met.
• CMS completing the final regulatory & contractual requirements.
• Launch expected early 2006
NOPR Status (as of February 2006)
• Operational details (“protocol”) finalized – Late 2005
  Took nearly a full year to develop
• Web-based data entry/database operational – Feb 2006
• Over 500 PET facilities pre-registered to participate
• CMS announces approval of the registry – Feb 14, 2006
• Go-live date set – Mar 6, 2006
Issues Prior to Launch: Determining Need for
Institutional Review Board (IRB) Approval and
Patient Informed Consent (as of 2/27/06)
• Is this research? Yes
• Is IRB approval needed? No
   – CMS has designated participation in the registry as
      “coverage with evidence development”.
   – Participation is required for Medicare reimbursement.
   – Thus, exempt from IRB approval under
      45 CFR 46.101(b)(5) for all 45 CFR part 46 requirements.
• Is IRB exemption required? Yes
   – Each PET facility must request exemption from its own IRB
      (or otherwise make determination of exempt status of registry).
• Is a research informed consent required? No
Solution: Institutional Review Board (IRB)
Approval and Subject Informed Consent
• Is this research? Yes, but only for the NOPR. Individual
  PET facilities and referring physicians are not engaged in
  research.
• Is IRB approval needed? Yes. ACR IRB has approved the
  NOPR. Individual PET facilities and referring physicians
  do not need to obtain IRB approval to participate.
   – All data will be sent to CMS. CMS is not engaged in research.
   – Patients and referring physicians will be given an IRB-approved
     information sheet and asked for consent to have their data included
     for NOPR research.
Startup Problems
• Not all carriers prepared to accept NOPR
  claims on June 19, 2006 (as required by CMS)
• Various billing issues (frequency limitations,
  non-cancer ICD-9 codes)
• Confusion about data entry deadlines
• Inclusion of covered cancers/indications under
  NOPR
   – Only cases where both patient and physician give consent
     will be included in the NOPR research dataset.
Startup Problems
• Some problems with completion of case report forms
  by referring physicians/staff members (e.g., logically
  inconsistent responses to related questions)
• Confusion about the meaning of “Diagnosis”
• Payments to referring physicians for form completion
• Charging of NOPR fee to patients
Major Problem with the NOPR Paradigm
• Only possible to collect limited data and difficult to
  control data quality
• Consequence of the self-funded model with non-
  engaged participants (You get what you pay for!)
• Tradeoff between data quantity/quality and access
Major Problem with the NOPR Paradigm:
Possible solutions
• Collecting more detailed clinical data and information
  about actual outcomes will require funding of
  participating sites/referring MDs
• Collecting better quality data will require more
  education of participants
   – Certification before participation
   – Require referring MDs to enter data on-line with logic
     checks and “wizards” to help guide responses
   – Audits/scrubbing of incoming data
• These steps will surely increase cost, limit access,
  and require IRB approval
NOPR Status as of April 3 2009 (date of new NCD)

• Opened for patient accrual on May 8, 2006
• 1,891 PET facilities nationwide participating
  (over 90% of all sites)
• 132,946 patients - data entry completed
• Approximately 92% of patients and 96% of referring
  physicians gave consenting for research use of data
• CMS expenditure of ~$125 million to provide NOPR
  PET scans

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:14
posted:1/20/2011
language:English
pages:26